Genprex adds Gabrail Cancer Center as new site for Acclaim-1 and Acclaim-3 Reqorsa trials

Genprex, Inc.

Gabrail Cancer Center (Canton, OH) is new clinical trial site for Acclaim-1 (NSCLC) and Acclaim-3 (ES-SCLC) studying Reqorsa gene therapy.
Acclaim-1 Phase 2 expansion to enroll ~33 patients; interim analysis after 19 patients, enrollment of first 19 expected H1 2026.
Acclaim-3 Phase 2 expansion to enroll ~50 patients; interim analysis after 25th patient, enrollment of first 25 expected H1 2026.
Both trials have FDA Fast Track Designation; Acclaim-3 also has Orphan Drug Designation.
Phase 1 showed no dose-limiting toxicities and early efficacy: some patients had prolonged progression-free survival, one partial response.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.